Ipilimumab, a Pioneer Breakthrough in Cancer Treatment - Forbes
May 20, 2024 · Although initially designed to treat advanced melanoma, doctors today may offer ipilimumab and other checkpoint inhibitors to treat several types of cancers. This article describes how...
Study finds increased survival with nivolumab plus ipilimumab vs.
Dec 9, 2024 · For patients with microsatellite-instability-high (MSI-H) or mismatch-repair-deficient (dMMR) metastatic colorectal cancer who had not previously received systemic treatment, progression-free...
Final, 10-Year Outcomes with Nivolumab plus Ipilimumab in …
Sep 15, 2024 · In the nivolumab-plus-ipilimumab group, melanoma-specific survival at 10 years was 87% among patients with a depth of response of at least 80% and was 72% among patients with a depth of...
Ipilimumab - latest research news and features - Medical Xpress
Ipilimumab (also known as MDX-010 or MDX-101), marketed as Yervoy, is a drug used for the treatment of melanoma, a type of skin cancer. It is a U.S. Food and Drug Administration (FDA) approved ...
Dual Immunotherapy Treatment Improves Progression-Free …
Jan 20, 2024 · The dual immunotherapy combination of nivolumab and ipilimumab reduced the risk of disease progression or death by 79% compared to chemotherapy with or without targeted therapies as first-line treatment in patients with microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer.
Pre- and post-surgical immunotherapy improves outcomes for …
May 15, 2024 · Mar. 16, 2023 — In a Phase II trial, adding ipilimumab to a neoadjuvant, or pre-surgical, combination of nivolumab plus platinum-based chemotherapy, resulted in a major pathologic response (MPR...
Nivolumab Plus Ipilimumab in Advanced Melanoma: Potential for …
Sep 23, 2024 · Nivolumab plus ipilimumab can provide long-term benefits to patients with advanced melanoma, according to a 10-year update of the CheckMate 067 trial.
FDA Grants Fast Track Designation to UV1 Vaccine Combo in …
Feb 6, 2024 · The FDA has granted fast track designation to UV1, an investigational cancer vaccine, plus nivolumab (Opdivo) and ipilimumab (Yervoy) in the management of unresectable malignant pleural mesothelioma, according to a press release from Ultimovacs ASA, the developer of the vaccine. 1
Nivolumab plus ipilimumab offers ‘potential for cure’ in ... - Healio
Sep 16, 2024 · Nivolumab monotherapy improved OS vs. ipilimumab monotherapy. The addition of nivolumab to ipilimumab conferred a long-term OS benefit for patients with advanced melanoma, according to study...
Ipilimumab with or without nivolumab in PD-1 or PD-L1 blockade …
Aug 17, 2023 · Ninety-two eligible patients were randomly assigned in a 3:1 ratio to receive the combination of ipilimumab and nivolumab, or ipilimumab alone. The primary endpoint was progression-free...